Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Aged 2 Years and Above
NCT06044077Phase 3Recruiting
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by AIM Vaccine Co., Ltd.. Started Sep 2023; status: recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06044077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044077.